These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 10390126)

  • 21. Pharmacological analysis of cyclooxygenase-1 in inflammation.
    Smith CJ; Zhang Y; Koboldt CM; Muhammad J; Zweifel BS; Shaffer A; Talley JJ; Masferrer JL; Seibert K; Isakson PC
    Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13313-8. PubMed ID: 9789085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors.
    Buttar NS; Wang KK
    Mayo Clin Proc; 2000 Oct; 75(10):1027-38. PubMed ID: 11040851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.
    Celotti F; Laufer S
    Pharmacol Res; 2001 May; 43(5):429-36. PubMed ID: 11394934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.
    Famaey JP
    Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defining COX-2 inhibitors.
    Lipsky PE
    J Rheumatol Suppl; 2000 Oct; 60():13-6. PubMed ID: 11032097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II).
    Taketo MM
    J Natl Cancer Inst; 1998 Nov; 90(21):1609-20. PubMed ID: 9811310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of cyclo-oxygenase-2.
    Stack E; DuBois RN
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):787-800. PubMed ID: 11566041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of inducible cyclooxygenase (COX-2) in inflammation.
    Seibert K; Masferrer JL
    Receptor; 1994; 4(1):17-23. PubMed ID: 8038702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct functions of COX-1 and COX-2.
    Morita I
    Prostaglandins Other Lipid Mediat; 2002 Aug; 68-69():165-75. PubMed ID: 12432916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scientific rationale for specific inhibition of COX-2.
    Bolten WW
    J Rheumatol Suppl; 1998 May; 51():2-7. PubMed ID: 9596548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Non-steroidal anti-inflammatory agents (NSAID's) with lesser side effects by selective inhibition of cyclo-oxygenase-2].
    Bijlsma JW; Van de Putte LB
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1762-5. PubMed ID: 9856140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclooxygenase in biology and disease.
    Dubois RN; Abramson SB; Crofford L; Gupta RA; Simon LS; Van De Putte LB; Lipsky PE
    FASEB J; 1998 Sep; 12(12):1063-73. PubMed ID: 9737710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclooxygenases 1 and 2.
    Vane JR; Bakhle YS; Botting RM
    Annu Rev Pharmacol Toxicol; 1998; 38():97-120. PubMed ID: 9597150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclooxygenase knockout mice: models for elucidating isoform-specific functions.
    Langenbach R; Loftin C; Lee C; Tiano H
    Biochem Pharmacol; 1999 Oct; 58(8):1237-46. PubMed ID: 10487525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Specific cyclooxygenase-2 inhibitors. Basis and options of a pharmacotherapeutic concept].
    Hinz B; Brune K
    Anaesthesist; 2000 Nov; 49(11):964-71. PubMed ID: 11151817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.
    Ermert L; Dierkes C; Ermert M
    Clin Cancer Res; 2003 May; 9(5):1604-10. PubMed ID: 12738712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclooxygenase 2 (COX-2) as a target for therapy and noninvasive imaging.
    Herschman HR; Talley JJ; DuBois R
    Mol Imaging Biol; 2003; 5(5):286-303. PubMed ID: 14630509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.